VBWG
Data alert

SECURE: ACE inhibition retards the progression of atherosclerosis

Final results of the Study to Evaluate Carotid Ultrasound changes with Ramipril and vitamin E (SECURE) have been published and confirm that treatment with ramipril 10 mg slows the progression of atherosclerosis, while treatment with vitamin E has no apparent effect. The findings in SECURE, a substudy of the Heart Outcomes Prevention Evaluation (HOPE) study, parallel the results of the main study. HOPE showed that ramipril significantly reduced MI, stroke, and death, while vitamin E had no significant effect on clinical outcomes. HOPE and SECURE together demonstrate that ramipril reduces atherosclerosis progression and prevents major vascular events.





DA6.ppt

Download DA6.ppt (5 slides - 0.3MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5
Data_Alert.pdf (0.3MB)Data_Alert.pdf (0.3MB)


ACEapparentAtherosclerosisCarotidinhibitionProgressionpublishedramiprilretardsSECUREslowsUltrasoundvitamin

Related at vwbg.org

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.

Vascular Biology in Clinical Practice © Vol. 7, No. 1

ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection

This monograph, ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection , which is being offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.
More related